A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso(R) (Treprostinil) Inhalation Solution
Phase of Trial: Phase IV
Latest Information Update: 19 Feb 2016
Price : $35 *
At a glance
- Drugs Treprostinil (Primary) ; Epoprostenol; Epoprostenol agonists; Treprostinil; Treprostinil; Type 5 cyclic nucleotide phosphodiesterase inhibitors
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms ASPIRE
- Sponsors United Therapeutics Corporation
- 17 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 24 Jun 2014 New trial record